Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines

Teng, WeiWeiTengChang, Ting-TsungTing-TsungChangYang, Hwai-IHwai-IYangPeng, Cheng-YuanCheng-YuanPengSu, Chien-WeiChien-WeiSuTUNG-HUNG SUHu, Tsung-HuiTsung-HuiHuYu, Ming-LungMing-LungYuHUNG-CHIH YANGWu, Jaw-ChingJaw-ChingWu2024-03-212024-03-212024-01-2219360533https://www.scopus.com/record/display.uri?eid=2-s2.0-85182805291&doi=10.1007%2fs12072-023-10634-6&origin=inward&txGid=006fad16496dd34da3053b9b2126e4f8https://scholars.lib.ntu.edu.tw/handle/123456789/641161Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.enCorrection to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelinescorrigendum10.1007/s12072-023-10634-6382523662-s2.0-85182805291https://api.elsevier.com/content/abstract/scopus_id/85182805291